Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Real-world study shows Paxlovid associated with lower hospitalization rates

Real-world study shows Paxlovid associated with lower hospitalization rates

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results

Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results

Evaluating efficacy of SARS-CoV-2 antivirals in a mouse model

Evaluating efficacy of SARS-CoV-2 antivirals in a mouse model

Researchers explore COVID-19 vaccination in immunocompromised individuals

Researchers explore COVID-19 vaccination in immunocompromised individuals

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

First oral antiviral approved for early treatment of COVID-19

First oral antiviral approved for early treatment of COVID-19

Outcomes of COVID-19 treatment with Paxlovid

Outcomes of COVID-19 treatment with Paxlovid

Oral Nirmatrelvir's effects on long COVID symptoms

Oral Nirmatrelvir's effects on long COVID symptoms

SARS-CoV-2 Mpro inhibitors built on rattlesnake venom scaffold

SARS-CoV-2 Mpro inhibitors built on rattlesnake venom scaffold

Thousands more vulnerable patients are eligible to receive the UK’s second antiviral for COVID-19

Thousands more vulnerable patients are eligible to receive the UK’s second antiviral for COVID-19

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

Study explores broad-spectrum, host-acting antiviral strategy to treat SARS-CoV-2

Study explores broad-spectrum, host-acting antiviral strategy to treat SARS-CoV-2

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

HIV patients on antiretroviral treatment with protease inhibitors may have lower COVID-19 risk

HIV patients on antiretroviral treatment with protease inhibitors may have lower COVID-19 risk

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2